LONDON, January 9, 2015 /PRNewswire/ --
Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai:
HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical
group, today notes that Takeda Pharmaceuticals U.S.A. Inc. ("Takeda") has been unsuccessful
in appealing the decision by the United States District Court for
the District of Delaware to deny
Takeda's motion for a preliminary injunction in relation to the
distribution of Hikma's colchicine 0.6mg capsules for the
prophylaxis of gout flares in adults. The injunction, which
was granted to Takeda on 9 October
2014, has been vacated.
Hikma will now prepare to distribute its colchicine, which it
will market under the brand name MITIGARE™. Hikma will also
be preparing to launch an authorised generic of MITIGARE™,
increasing patient access to this important product.
Said Darwazah, Chairman and CEO of Hikma, said:
"I am very pleased to be launching our colchicine products,
demonstrating our success in developing a more differentiated
product portfolio for the US market."
According to IMS Health, sales of colchicine in the US market
were approximately $688 million for
the 12 months ending August 2014.
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Branded",
"Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market
leader, the United States and
Europe. In 2013, Hikma
achieved revenues of $1,365 million
and profit attributable to shareholders of $212 million.
Enquiries
Hikma Pharmaceuticals
PLC
Susan Ringdal, VP Corporate Strategy
and Director of Investor
Relations +44(0)20-7399-2760
Lucinda Henderson, Deputy Director
of Investor
Relations +44(0)20-7399-2765
FTI
Consulting
Ben Atwell/ Matthew Cole/ Julia
Phillips
+44(0)20-3727-1000
